Systemix Report issue

For profit Phase 2
Founded: Palo Alto CA United States (1987)
Status: Acquired by Novartis (1997)

Organization Overview

First Clinical Trial
1998
NCT00003942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1998

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

revm10 gene (1 trial)

revm10/polas gene (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2